JP2014518240A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518240A5
JP2014518240A5 JP2014517749A JP2014517749A JP2014518240A5 JP 2014518240 A5 JP2014518240 A5 JP 2014518240A5 JP 2014517749 A JP2014517749 A JP 2014517749A JP 2014517749 A JP2014517749 A JP 2014517749A JP 2014518240 A5 JP2014518240 A5 JP 2014518240A5
Authority
JP
Japan
Prior art keywords
structural formula
compound
thiadiazole
piperazine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518240A (ja
JP5972367B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/062778 external-priority patent/WO2013004642A1/en
Publication of JP2014518240A publication Critical patent/JP2014518240A/ja
Publication of JP2014518240A5 publication Critical patent/JP2014518240A5/ja
Application granted granted Critical
Publication of JP5972367B2 publication Critical patent/JP5972367B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517749A 2011-07-01 2012-06-29 神経変性疾患の治療に有用な1,2,4−チアジアゾール−5−イルピペラジン誘導体 Expired - Fee Related JP5972367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11172324.3 2011-07-01
EP11172324 2011-07-01
PCT/EP2012/062778 WO2013004642A1 (en) 2011-07-01 2012-06-29 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2014518240A JP2014518240A (ja) 2014-07-28
JP2014518240A5 true JP2014518240A5 (https=) 2015-05-28
JP5972367B2 JP5972367B2 (ja) 2016-08-17

Family

ID=46545347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517749A Expired - Fee Related JP5972367B2 (ja) 2011-07-01 2012-06-29 神経変性疾患の治療に有用な1,2,4−チアジアゾール−5−イルピペラジン誘導体

Country Status (9)

Country Link
US (1) US9023852B2 (https=)
EP (1) EP2726470B1 (https=)
JP (1) JP5972367B2 (https=)
CN (1) CN103619825B (https=)
AU (1) AU2012280420B2 (https=)
CA (1) CA2837247C (https=)
ES (1) ES2540956T3 (https=)
PL (1) PL2726470T3 (https=)
WO (1) WO2013004642A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2744798T3 (pl) 2011-08-17 2016-08-31 Remynd Nv Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera
WO2015140130A1 (en) * 2014-03-17 2015-09-24 Remynd Nv Oxadiazole compounds
AU2017281907B2 (en) * 2016-06-23 2021-10-21 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR102728619B1 (ko) 2017-12-27 2024-11-08 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
EP3731859B1 (en) 2017-12-27 2025-08-20 St. Jude Children's Research Hospital, Inc. Pyridazine compounds for use to treat disorders associated with castor
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2025104092A1 (en) 2023-11-13 2025-05-22 Remynd N.V. Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1161424E (pt) * 1999-03-03 2004-08-31 Wyeth Corp Novos derivados de diazole como agentes serotonergicos
CA2367695A1 (en) * 1999-04-26 2000-11-02 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine
PE20070099A1 (es) * 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
WO2007092435A2 (en) * 2006-02-07 2007-08-16 Wyeth 11-beta hsd1 inhibitors
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases

Similar Documents

Publication Publication Date Title
JP2014518240A5 (https=)
JP2010516681A5 (https=)
RU2015143643A (ru) Соль омекамтива мекарбила и способ ее получения
JP2009533369A5 (https=)
RU2010145171A (ru) Аналоги галихондрина в
JP2016512822A5 (https=)
JP2018528182A5 (https=)
BG65029B1 (bg) Триазолови съединения и използването им като допамин-d3-лиганди
EP3484895A1 (en) Solid state forms of crisaborole
EP2906554A1 (en) Solid forms of nilotinib hydrochloride
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
JP2011105685A (ja) フェネチルアミン化合物の結晶
CN102295655A (zh) 一种氧头孢烯类抗菌素中间体溶剂化物及其制备方法
US3509153A (en) 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
JP4613501B2 (ja) 5−保護アミノピリミジン化合物の製造方法
Boland et al. Routes to novel mono-and bis-tetrazole compounds: synthesis, spectroscopic and structural characterization
US9518033B2 (en) (4E)-4-(4-substituted benzylideneamino)-2,3-dihydro-3-substituted-2-thioxothiazole-5-carbonitriles as A2AR antagonist and process for preparation thereof
JP5004643B2 (ja) N−(2−アミノ−1,2−ジシアノビニル)ホルムアミジンの製造方法
KR102702677B1 (ko) 피마살탄 및 그의 제조 중간체의 제조방법
IL291569B1 (en) Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine
JP2017514845A5 (https=)
CN103880750A (zh) 一种替格列汀关键中间体的制备方法
CN102229578A (zh) 一种2-芳胺基-1,3,4-噁二唑化合物的制备方法
Fathalla Syntheses and reactions of methyl [3-(4-phenyl-thiazol-2-yl)-thioureido] alkanoates and related compounds
CN105037331B (zh) 瑞舒伐他汀中间体的制备方法